Research Article
Therapeutic Plasma Exchange as a Treatment for Autoimmune Neurological Disease
| | | General,n = 187 | MG,n = 70 | GBS, n = 53 | NMOSD,n = 35 | CIDP,n = 23 | AE, n = 6 |
| | Days of inpatient stay, median (IQR) | | | | | | | | Inhospital stay | 12 (8–19) | 11 (7–15) | 13 (9–33) | 12 (8–18) | 10 (7–16) | 24.5 (17–49) | | ICU stay | 7 (6–12) | 7 (6–10) | 9 (6–24) | 6 (6–9) | 6 (6–8) | 10 (6–15) |
| | Complications, n (%) | | | | | | | | Hypotension | 106 (56.6) | 35 (50) | 35 (66) | 17 (48.5) | 15 (65.2) | 4 (66.6) | | Hydroelectrolytic disorders | 102 (54.5) | 35 (50) | 30 (56.6) | 23 (65.7) | 11 (47.8) | 3 (50) | | Related to Mahurkar catheter | 85 (45.4) | 29 (41.2) | 26 (49) | 15 (42.8) | 12 (52.1) | 3 (50) | | Bleeding | 56 (29.9) | 22 (31.4) | 19 (35.8) | 9 (25.7) | 4 (17.3) | 2 (33.3) | | Infections | 21 (11.2) | 5 (7.1) | 10 (18.8) | 4 (11.4) | 2 (8.6) | 0 | | Thrombosis | 4 (2.1) | 1 (1.4) | 3 (5.6) | 0 | 0 | 0 | | Hypersensibility | 2 (1) | 1 (1.4) | 0 | 0 | 0 | 1 (16.6) | | Arrhythmias | 2 (1) | 1 (1.4) | 0 | 1 (2.8) | 0 | 0 | | Hemolysis | 0 | 0 | 0 | 0 | 0 | 0 |
| | Death during hospitalization, n (%) | | | | | | | | | 3 (1.6) | 0 | 1 (1.8) | 0 | 2 (8.6) | 0 |
| | Relapse during the year after, n (%) | | | | | | | | Number of patients | 59 (31.5) | 33 (47.1) | 3 (5.6) | 14 (40) | 7 (30.4) | 2 (33.3) |
|
|
MG, myasthenia gravis; GBS, Guillain–Barré syndrome; NMOSD, neuromyelitis optica spectrum disorders; CIDP, chronic inflammatory demyelinating polyneuropathy; AE, autoimmune encephalitis IQR, interquartile range; ICU, intensive care unit.
|
